BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 07, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CX1739: Phase II data

Top-line data from a double-blind, placebo-controlled Phase II trial in 20 adults with moderate to severe obstructive sleep apnea showed that a single oral dose of 900 mg CX1739 did not reduce mean apnea-hypopnea index (AHI) score, defined as the frequency of apnea or hypopnea events per hour of sleep, from baseline. Cortex said the interpretation of the results was "complicated" by a reduced sleep time during the night following treatment. In an AHI responder analysis, defined as a >40% reduction in AHI score, 3 patients receiving CX1739...

Read the full 419 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >